1. Cancer patients often have high levels of the membrane-bound enzyme cyclooxygenase.
2. Most cancer treatments attempt to limit these high levels of cyclooxygenase. However, Dr. Qian says that cyclooxygenase inhibitors can injure the gastrointestinal tract and increase risk of cardiovascular disease.
3. Rather than inhibiting cyclooxygenase, Dr. Qian and his research team plan to research cyclooxygenase to see if the enzyme can be used to control cancer growth.
4. The researchers hope to use their findings to create therapies that combat colon cancer, while also decreasing the side effects of chemotherapy.
5. This grant was awarded by two parts of the NIH — the National Cancer Institute and the National Institute of General Medical Sciences.
More articles on gastroenterology and endoscopy:
Gastroenterologists and physician groups ask CMS to cover virtual colonoscopy: 6 points
Study links facial skin condition to gastrointestinal disorders: 5 insights
United Network for Organ Sharing proposes new way to distribute liver transplants: 6 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
